Proactive Investors - Run By Investors For Investors

Heritage Cannabis to acquire stake in DNA-testing cannabis company Endocanna

The LA company has created a DNA test that uses a saliva sample to identify an individual's genetic variants related to cannabinoid receptors and metabolism
"Acquisition" highlighted
Individual's genetic data can be used to guide cannabis strain and dosage decisions

Heritage Cannabis Holdings Corp (CSE:CANN) signed a letter of intent Wednesday to acquire 30% of Endocanna Health Inc in a $3 million deal.

Los Angeles-based Endocanna has created the Endocannabinoid DNA test that uses a saliva sample to identify an individual's genetic variants related to cannabinoid receptors and metabolism.

That data can then be used to guide users' strain and dosage decisions.

WATCH: Heritage Cannabis finishes large fund raise, purchases facility in Ft Erie, Ontario

As part of the deal, the companies will form a joint venture to represent the EndoDNA technology in Canada. The deal is expected to close by June 28. 

"We are excited to be combining our plans for our own Extraction and Medical Sciences divisions with the technology and expertise that Endocanna brings." Chief Science Officer Chris Spooner said. "By utilizing the science-based EndoDNA process, we will be better able to assist patients with selecting and dosing by developing formulations that address the unique pharmacogenomics of individuals."

Heritage is a Canadian cannabis provider focused on becoming a vertically integrated company. It currently owns Voyage Cannabis Corp and CannaCure Corp, two Health Canada-approved cannabis producers.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CANN profile View Profile

Heritage Cannabis Timeline

Related Articles

RYAH vaporizer and cartridges
May 16 2019
RYAH is the first cannabis vaporizer that lets users precisely regulate dose and temperature
cannabis leaf
May 08 2019
The company plans to leverage its portfolio of brands as well as its distribution network of more than 39,000 European pharmacies to maximize margins and profitability
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use